To examine whether inhibition of CD47 can sensitize the inhibitory effect of EGFR inhibitors on tumor growth, we treated the mice bearing the brain tumor derived from CT‐2A glioma cells with EGFR inhibitor afatinib or an anti‐CD47 antibody alone or with a combination of both reagents. This evidence concerns the gene EGFR and central nervous system cancer.